← Blog · Mother Health · · 6 min read

Insulin Resistance in Pregnancy: The Physiology Behind Gestational Diabetes

Why the placenta causes insulin resistance in pregnancy, who is most at risk, and how it becomes gestational diabetes when the body can't keep up.

Insulin resistance is a normal, expected feature of pregnancy. Beginning in the second trimester, the placenta secretes hormones — including human placental lactogen, progesterone, cortisol, and growth hormone — that reduce insulin sensitivity in the mother's peripheral tissues. The biological purpose is to increase circulating glucose, making more fuel available to the fetus. A healthy pancreas compensates by producing more insulin. When it cannot, blood glucose rises, and gestational diabetes mellitus (GDM) develops.

This article focuses on the underlying physiology and clinical risk factors. For a practical patient guide to GDM — testing, diet, monitoring, and medication — see Living Well With Gestational Diabetes.

The physiology: why pregnancy induces insulin resistance

Insulin is an anabolic hormone produced by pancreatic beta cells. Its primary role is to promote glucose uptake into skeletal muscle, adipose tissue, and the liver, while suppressing hepatic glucose output. In pregnancy, placental hormones antagonise insulin signalling at the receptor and post-receptor level. By the third trimester, insulin sensitivity can drop to 50–70% of pre-pregnancy levels.

This is not a malfunction. It is an adaptation. The maternal metabolism shifts toward a catabolic state in the fasting period and an exaggerated anabolic state after meals, channelling glucose toward the placenta even when maternal tissues would normally absorb it. The fetus receives a steady supply of glucose, amino acids, and free fatty acids — the building blocks of rapid growth.

The system works as long as pancreatic beta cells can hypersecrete enough insulin to overcome the resistance. When they cannot, maternal hyperglycaemia results. This is the central mechanism of GDM.

From physiological resistance to gestational diabetes

GDM is defined as glucose intolerance first recognised during pregnancy, in women who were not previously diabetic. It affects approximately 6–14% of pregnancies worldwide, though prevalence varies by population, diagnostic criteria, and obesity rates.

The path from normal resistance to GDM depends on several factors:

  • Beta-cell reserve: Women with limited pancreatic capacity — often due to genetics, prior beta-cell strain, or autoimmune damage — cannot match the demand.
  • Pre-existing insulin resistance: Obesity, polycystic ovary syndrome (PCOS), and a sedentary lifestyle amplify baseline resistance, leaving less margin before glucose rises.
  • Genetic susceptibility: Variants in genes such as TCF7L2, KCNJ11, and IRS1 increase risk, overlapping with type 2 diabetes genetics.
  • Age: Pancreatic function declines with age. Women over 35 have higher GDM rates.

Importantly, GDM usually resolves after delivery as placental hormones clear, but the underlying metabolic vulnerability often persists. Women with GDM have a 7-fold increased lifetime risk of developing type 2 diabetes.

PCOS, obesity, and pre-existing resistance

Some women enter pregnancy already insulin-resistant. Polycystic ovary syndrome is the clearest example: hyperandrogenism and beta-cell stress predate conception, and pregnancy simply unmasks what was already there. Obesity acts similarly, with adipose tissue producing inflammatory cytokines (TNF-α, IL-6) that further impair insulin signalling. These women face higher GDM rates, earlier onset (often before 24 weeks), and a greater likelihood of needing pharmacological treatment.

Identifying pre-existing insulin resistance before pregnancy — through fasting glucose, HbA1c, or fasting insulin testing — allows for preconception counselling, lifestyle optimisation, and earlier screening once pregnant.

Why hyperglycaemia harms the fetus

Glucose crosses the placenta freely; maternal insulin does not. When maternal glucose rises, the fetus is exposed to the same elevated levels and responds by hypersecreting its own insulin. Fetal hyperinsulinaemia drives:

  • Macrosomia — particularly truncal and shoulder adiposity, raising shoulder dystocia risk.
  • Neonatal hypoglycaemia — when the maternal glucose supply ends at delivery but fetal insulin remains high.
  • Delayed lung maturation — hyperinsulinaemia interferes with surfactant production, contributing to respiratory distress.
  • Polyhydramnios — fetal osmotic diuresis from sustained hyperglycaemia.
  • Pre-eclampsia — insulin resistance and endothelial dysfunction share overlapping pathways.

Long-term, intrauterine exposure to hyperinsulinaemia is associated with higher childhood obesity and impaired glucose tolerance — a phenomenon known as fetal metabolic programming.

The long-term significance for the mother

Pregnancy functions as a metabolic stress test. A woman whose pancreas cannot meet pregnancy's insulin demand has, by definition, reduced beta-cell reserve. This is why GDM is one of the strongest predictors of future type 2 diabetes: roughly 50% of women with GDM will develop it within 10–20 years. Cardiovascular disease risk is also elevated.

Lifestyle interventions begun in pregnancy and continued postpartum — sustained weight management, physical activity, and breastfeeding — measurably reduce that long-term risk. The pregnancy diagnosis is, in this sense, a preview and an opportunity.

The clinical takeaway

Insulin resistance in pregnancy is not a disease — it is a designed adaptation that exposes underlying metabolic capacity. GDM is what happens when that capacity is exceeded. Understanding the mechanism clarifies why some women develop it despite faultless behaviour, why others remain euglycaemic on poor diets, and why the postpartum window matters as much as the pregnancy itself. For practical management — screening, glucose targets, diet, exercise, and medication — see our companion guide: Living Well With Gestational Diabetes.

Sources and further reading

  • International Association of Diabetes and Pregnancy Study Groups (IADPSG). "International Association of Diabetes and Pregnancy Study Groups Recommendations on the Diagnosis and Classification of Hyperglycemia in Pregnancy." Diabetes Care, 2010. diabetesjournals.org
  • American College of Obstetricians and Gynecologists (ACOG). "Gestational Diabetes Mellitus." Practice Bulletin No. 190. www.acog.org
  • National Institute for Health and Care Excellence (NICE). "Diabetes in Pregnancy: Management from Preconception to the Postnatal Period." NG3. www.nice.org.uk
  • Battarbee AN et al. "Management of Gestational Diabetes Mellitus." BMJ, 2020. www.bmj.com
  • Metzger BE et al. "Hyperglycemia and Adverse Pregnancy Outcomes." New England Journal of Medicine, 2008. PubMed
  • World Health Organization (WHO). "Diagnostic Criteria and Classification of Hyperglycaemia First Detected in Pregnancy." 2013. www.who.int

This article is for educational purposes and does not replace medical advice from your obstetrician, endocrinologist, or diabetes care team. If you have concerns about glucose testing, results, or management during pregnancy, discuss them directly with your healthcare provider.

Related articles